Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)

• Status: Completed
• Trial end date: 1997-04-01

Summary

This is a Phase II/Phase III study of intravesical AD 32 (valrubicin) in patients with carcinoma in situ (CIS) who have been previously treated with intravesical Bacillus Calmette-Guerin (BCG) for CIS and in whom recurrence or failure has occurred after multiple courses of intravesical treatment.

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Endo Pharmaceuticals
• Treatments: BCG Vaccine; Doxorubicin; Valrubicin